

# *NOD2* gene mutations in ulcerative colitis: useless or misunderstood?

Paulo Freire · Ricardo Cardoso · Pedro Figueiredo · Maria M. Donato · Manuela Ferreira · Sofia Mendes · Ana Margarida Ferreira · Helena Vasconcelos · Francisco Portela · Carlos Sofia

Accepted: 9 March 2014  
© Springer-Verlag Berlin Heidelberg 2014

## Abstract

**Purpose** *NOD2* mutations have been linked to an increased risk of Crohn's disease and to some of its phenotypes. The association between *NOD2* mutations and susceptibility to ulcerative colitis (UC) remains somewhat controversial and potential correlations between these mutations and UC phenotype have not been studied.

**Aim** To assess whether *NOD2* mutations are a risk factor for UC in Portugal and if there are any genotype–phenotype correlations in these patients.

**Methods** The three main *NOD2* mutations were searched in 200 patients with UC and in 202 healthy controls.

**Results** *NOD2* mutations were present in 28 patients with UC (14.0 %) and in 27 controls (13.4 %) ( $p=0.853$ ). Mutation carriers were more likely to receive steroids during the first

year of disease than non-carriers (54.2 % vs. 29.6 %,  $p=0.018$ ) and among these patients the need for intravenous administration was more frequent in those with the R702W polymorphism (90.0 % vs. 45.5 %,  $p=0.014$ ). In patients with severe colitis admitted for intravenous steroids, a greater proportion of mutation carriers was considered intravenous-steroid refractory and required salvage therapy (90.0 % vs. 38.1 %,  $p=0.004$ ). Patients with *NOD2* mutation were submitted to colectomy more frequently than non-carriers (17.9 % vs. 4.1 %,  $p=0.015$ ). No correlation with the need for immunosuppressants/immunomodulators was found.

**Conclusions** In the Portuguese population, *NOD2* mutations do not increase the risk of UC but are associated with a more aggressive course including greater need of steroids in the first

Paulo Freire and Ricardo Cardoso contributed equally to the article.

P. Freire (✉) · R. Cardoso · P. Figueiredo · M. Ferreira · S. Mendes · A. M. Ferreira · F. Portela · C. Sofia  
Department of Gastroenterology, Centro Hospitalar e Universitário de Coimbra, Avenida Bissaya Barreto, 3000 Coimbra, Portugal  
e-mail: pauloavfreire@gmail.com

R. Cardoso  
e-mail: racardoso@gmail.com

P. Figueiredo  
e-mail: pnfl1@sapo.pt

M. Ferreira  
e-mail: malvesferreira@netcabo.pt

S. Mendes  
e-mail: msosiamendes@iol.pt

A. M. Ferreira  
e-mail: magaidaferreira@gmail.com

F. Portela  
e-mail: fasportela@gmail.com

C. Sofia  
e-mail: carlossofia@huc.min-saude.pt

P. Figueiredo · M. M. Donato · C. Sofia  
Center of Gastroenterology, Faculty of Medicine,  
University of Coimbra,  
Avenida Bissaya Barreto, 3000 Coimbra, Portugal

M. M. Donato  
e-mail: mariamanueldonato@gmail.com

H. Vasconcelos  
Department of Gastroenterology, Centro Hospitalar Leiria-Pombal,  
Rua das Olhalvas, 2410-197 Leiria, Portugal  
e-mail: hml.vasconcelos@gmail.com

year, increased incidence of intravenous-steroid refractoriness and a higher colectomy rate.

**Keywords** Ulcerative colitis · *NOD2* mutations · Genotype–phenotype correlations · Disease course · Prognosis

## Introduction

The inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD), are chronic relapsing and remitting inflammatory conditions affecting the gastrointestinal tract. They are likely the result of a dysregulated immune response to the gut microflora in genetically predisposed individuals [1].

Over the past two decades, investigators have used whole genome linkage and genome-wide association studies, to identify over 163 genetic loci containing susceptibility genes for IBD [2]. These loci, although nearly all low-risk, have provided important lessons regarding IBD etiopathogenesis, including that UC and CD are related polygenic IBDs, with distinct and overlapping susceptibility loci [2, 3].

Although UC and CD share associations with many single-nucleotide polymorphisms (SNPs) in Th17/IL22-23 axis, adaptive immunity and epithelial barrier function, there are divergences between the two diseases in the *NOD2* and autophagy pathway SNPs which are both associated with CD but not UC [2, 4, 5].

*NOD2*, located on chromosome 16, was one of the earliest genes in which mutations have been shown to be associated with IBD [6, 7]. This gene encodes a protein that functions as an intracellular sensor of muramyl-dipeptide, a component of bacterial cell walls [8]. Therefore, *NOD2* mutations compromise host response to enteric bacteria [8]. Three major *NOD2* SNPs, two missense [R702W, G908R] and one frameshift (1,007 fs), were shown by independent groups to be associated with susceptibility to CD [6, 7, 9–11]. By contrast, even though most available data showed no link between *NOD2* mutations and susceptibility to UC, a few recent studies have reached different conclusions, and so this matter remains somewhat controversial [4, 5, 10, 12–15].

Great efforts have been made to predict disease behavior and response to treatment in IBD [16–19]. Such understanding could personalize therapy, namely early introduction of more aggressive therapies to patients at high risk or avoiding starting predictably ineffective treatments. Indeed, the ultimate goal in the genomic study of IBD is to identify biologically relevant genotype–phenotype associations and to apply them to clinical practice [17, 20].

Patients with UC demonstrate a certain degree of heterogeneity as the age of onset, disease extent, natural history, response to medical therapies, and need for surgery vary between individuals [17, 21, 22]. Among the UC

susceptibility genes, HLA DRB1\*0103 and the multidrug resistance gene 1 (MDR1/ABCB1) also contribute to clinical phenotype and natural history, being associated with extensive and severe disease [17, 23–37]. In CD, *NOD2* gene mutations have repeatedly been shown to be associated with ileal disease, early age of onset, stricturing, and/or penetrating phenotype and increased need for surgery [5, 9, 10, 38–49].

Surprisingly, there are no studies focusing on potential genotype–phenotype associations between *NOD2* mutations and UC, perhaps because it is not commonly considered a susceptibility gene for UC [5, 10, 50]. All genotype–phenotype UC association studies focus on genes that had previously been identified as susceptibility genes for the disease [5, 17]. Nevertheless, this may produce a bias, since one gene not related with increased susceptibility to a disease may be associated with a particular phenotype of this disease. Indeed, this lesson can clearly be taken from the study of Seghal et al. [20]. In this work, even though *NOD2* mutations were not associated with the overall risk of pouchitis, a relation between the mutation carrier status and severe pouchitis was found [20]. Thus, the authors concluded that preoperative assessment of *NOD2* in ileal pouch-anal anastomosis candidates may predict severe pouchitis and might assist in preoperative surgical decision making [20].

In light of these data, we aimed to investigate if *NOD2* mutations increase susceptibility to UC in Portugal and whether there are genotype–phenotype correlations in these patients.

## Methods

### Patients and controls

In this case-control study, 200 Portuguese patients with UC (male/female, 86/114; mean age at diagnosis of UC  $34.8 \pm 14.4$  years old) and 202 healthy (blood donors) sex-matched controls, were genotyped for the three main *NOD2* mutations (R702W, G908R, and 3020insC). UC patients were consecutively recruited from a gastroenterology department in the inpatient and outpatient setting. The inclusion criteria for all study participants included Caucasian ethnicity and residency in the central region of Portugal and, for UC patients, a confirmed disease diagnosis based on established clinical, endoscopic, radiological, and histological criteria [51–53]. Patients with CD or colonic inflammatory bowel disease unclassified (IBDU) were excluded from the study.

Genomic DNA was isolated from whole blood in all the study participants.

Detailed phenotypic characteristics, including demographic data and clinical parameters, were obtained with a standardized questionnaire filled out by reviewing the medical charts and a patient interview at the time of enrolment. Phenotypic characteristics were classified

according to the recently published second European evidence-based consensus on the diagnosis and management of UC [54–56]. All phenotypic data were collected blind to the results of the genotypic data.

Correlations between *NOD2* mutations and UC phenotypic characteristics were sought. The associations with statistical significance in the univariate analysis were then tested in multivariate analysis using age at diagnosis and extent of disease as covariates since these are the factors most often and consistently described as having prognostic value in UC [57].

This study was approved by the local Ethics Committee and informed consent was obtained from all participants prior to enrolment into the study, in accordance with the Declaration of Helsinki.

#### Sample DNA extraction and genotyping

Genomic DNA was isolated from whole blood in accordance with the QIAamp Mini Kit (QIAGEN GmbH, Germany).

All participants were genotyped for the three major *NOD2* mutations: 3020insC (SNP13), R702W (SNP8) and G908R (SNP12). Genotyping was performed by real-time polymerase chain reaction (PCR): 3020insC variant using SimpleProbe and variants R702W and G908R using HybProbe (FRET). In order to detect the 3020insC variant, PCR was carried out using the forward primer 5'-gACAggTgggCTTCAGTAGA-3', the reverse primer 5'-TgAggTTCggAgAgCTAAACAg-3' and the simple probe 5'-CTgCaggCCCCTTgAAA-FLQ. The R702W variant was amplified and detected using the forward primer 5'-AgCCgCACAACTTAGATCAC-3', the reverse primer 5'-gCgggCACaggCATAgC-3', the anchor probe 5'-LC Red 640-gTCTggCACTCAGCCAgCaggCCCC-PH and the donor probe 5'-gCgCCAgAgCaggCCTTCTCA-FL. For assay of the G908R mutation, 5'-gCACATATCaggTACTCACTgAACT-3' was used as the forward primer, 5'-TTACTgAgCCACCTCAAGC-3' as the reverse primer, 5'-LC Red705-CTgAAAaggCCAAAAGgTCAACAgAC-PH as the anchor probe and the 5'-CCACTCTgTTgCCCCAgAA-FL as the donor probe.

The reaction mixture consisted of 18 µl of the PCR master mix plus 2 µl of the DNA of each patient. The PCR master mix for the R702W variant included 5.0 mM MgCl<sub>2</sub>, 1× LightCycler DNA master hybridization probes (Roche, Mannheim, Germany), 0.5 µM each primer and 0.1 µM each fluorescein and LC-Red-640-labeled probe. Cycling parameters consisted of 1 cycle of 95 °C for 2 min., followed by amplification for 45 cycles of 95 °C for 0 s, 55 °C for 10 s, and 72 °C for 5 s. A melting curve was created by measuring the fluorescent signal generated with the following profile: 95 °C for 5 s, 50 °C for 10 s, and 90 °C for 0 s with a slope 0.4 °C/s

transition. The PCR master mix for the G908R mutation included 2.5 mM MgCl<sub>2</sub>, 1× LightCycler DNA master hybridization probes (Roche, Mannheim, Germany), 0.5 µM each primer and 0.2 µM each fluorescein and LC-Red-705-labeled probe. Cycling parameters consisted of 1 cycle of 95 °C for 2 min., followed by amplification for 40 cycles of 95 °C for 10 s, 57 °C for 8 s, and 72 °C for 17 s. A melting curve was originated by measuring the fluorescent signal generated with the following profile: 95 °C for 20 s, 40 °C for 20 s, and 85 °C for 0 s with a slope 0.2 °C/s transition. Finally, the PCR master mix for the 3020insC variant included 2.5 mM MgCl<sub>2</sub>, 1× LightCycler DNA master hybridization probes (Roche, Mannheim, Germany), 0.2 µM forward primer, 0.5 µM reverse primer and 0.2 µM simple probe. Cycling parameters consisted of 1 cycle of 95 °C for 2 min, followed by amplification for 40 cycles of 95 °C for 10 s, 55 °C for 10 s, and 72 °C for 20 s. A melting curve was created by measuring the fluorescent signal generated with the following profile: 95 °C for 20 s, 40 °C for 20 s, and 85 °C for 0 s with a slope 0.2 °C/s transition. Sterile water was used as a negative control. The change of fluorescence was converted to a melting peak (T<sub>m</sub>) by plotting the negative derivative of the fluorescent signal corresponding to the temperature (−dF/dT) with the LightCycler software.

The sequence variations of the PCR products were confirmed by DNA sequencing.

#### Statistical analysis

Continuous variables were summarized using means and standard deviation and categorical variables were expressed as frequency and percentage. Standard tests were used to compare means and proportions: Student's *t* test or Wilcoxon rank-sum test for continuous variables and Mann-Whitney *U* Test, Chi-Square or Fisher's Exact Test for categorical variables, when appropriate.


Multivariate analysis was performed by logistic regression for each outcome that showed a significant correlation with *NOD2* mutations in the univariate analysis using age at diagnosis and maximum extent of disease as additional covariates.

Colectomy-free survival was calculated with the Kaplan-Meier method and the log-rank test was employed to make comparisons between groups. Data were censored at the time of colectomy or at the patient's last recorded visit.

Only *p* values <0.05 were considered significant and all *p* values presented are two-tailed.

Each genetic variant studied was in Hardy-Weinberg equilibrium.

The data was analyzed using the IBM SPSS Statistics (IBM Co., Armonk, NY, USA) computer software for Windows (version 20.0).



**Fig. 1** Genotype frequencies of the *NOD2* variants in UC patients and sex-matched controls

## Results

### *NOD2* mutation frequency

*NOD2* mutations were found in 28 patients with UC (including one R702W homozygote, one compound heterozygote R702W/G908R and another compound heterozygote G908R/3020insC) corresponding to a prevalence of 14.0 %. The most frequent polymorphism was R702W, present in 21 patients (10.5 %). The combined frequency of the three tested SNP's was similar between the study population and the sex-matched controls, as was the frequency of each individual genotype (Fig. 1). The *NOD2* allele frequencies were in Hardy-Weinberg equilibrium in all patients and in control subjects.

### Study population

#### *Demographic characteristics*

The demographic characteristics of the study population are summarized in Table 1. As shown, there are no significant differences between carriers and non-carriers of *NOD2* mutations concerning age at diagnosis, gender, family history or

smoking habits. Overall mean follow-up, considered as the time passed between diagnosis and last visit or colectomy, was  $180.26 \pm 105.60$  months.

#### *Extent of disease*

Regarding the maximum extent of disease, 17 (8.6 %) patients had proctitis, 84 (42.6 %) distal colitis and 96 (48.7 %) extensive colitis. There were no significant differences in the extent of the disease (proctitis/distal colitis/extensive colitis) between patients with and those without *NOD2* mutations (respectively, 11.1 %/37.0 %/51.9 % vs. 8.2 %/43.5 %/48.2 %;  $p=0.865$ ).

#### *First year of disease*

When evaluating the disease course during the first year following diagnosis, we observed that a greater proportion of patients with a *NOD2* mutation required at least one course of steroids compared with non-carriers: 54.2 % (13 patients) as compared with 29.6 % (42 patients) ( $p=0.018$ ) (Table 2).

Among steroid-treated patients, even though the percentage of patients admitted for intravenous steroids was superior in the group of the mutation carriers [9 patients (75.0 %) vs. 20 patients (47.6 %)], it did not reach statistical significance ( $p=0.113$ ). Nevertheless, the carriers of the R702W variant were more likely to need the intravenous route than non-carriers of this specific mutation [9 patients (90.0 %) vs. 20 patients (45.5 %),  $p=0.014$ ] (Table 2).

#### *Severe colitis*

A total of 52 patients (26.0 % of the study population) had at least one episode of severe colitis, defined as a flare with severe activity according Truelove and Witts criteria and requiring admission and treatment with intravenous steroids [54, 58]. There was no difference in the incidence of this event between genotype groups (Table 3). Significantly more patients with *NOD2* carrier status were intravenous-steroid

**Table 1** Demographic characteristics of the study population

Variables		All Patients	Carriers	Non-carriers	<i>p</i>
Age at diagnosis	A1/A2/A3 <sup>a</sup>	3.0 %/65.5 %/31.5 %	7.1 %/57.1 %/35.7 %	2.3 %/66.9 %/30.8 %	0.882
	mean $\pm$ SD <sup>b</sup>	34.83 $\pm$ 14.41	35.43 $\pm$ 14.26	34.73 $\pm$ 14.48	0.811
Male <i>n</i> (%)		86 (43.0 %)	12 (42.9 %)	74 (43.0 %)	0.987
Positive family history for IBD <i>n</i> (%)		25 (12.5 %)	5 (17.9 %)	20 (11.6 %)	0.359
Positive smoking history <i>n</i> (%)		40 (20.0 %)	5 (17.9 %)	35 (20.3 %)	0.760

SD Standard deviation; IBD inflammatory bowel disease

<sup>a</sup> A1 <16, A2 16–40, A3 >40 years; according Montreal classification [54, 58]

<sup>b</sup> Values in years

**Table 2** First year of disease

Variables	All <i>NOD2</i> mutations			R702W polymorphism		
	Carrier (%)	Non-carrier (%)	<i>p</i>	Carrier (%)	Non-carrier (%)	<i>p</i>
≥1 flare requiring steroids <sup>a</sup>	54.2 %	29.6 %	0.018	55.6 %	30.4 %	0.032
≥1 admission for IV steroids <sup>b</sup>	75.0 %	47.6 %	0.113	90.0 %	45.5 %	0.014

IV intravenous

<sup>a</sup> Data available in 166 patients<sup>b</sup> Data available in 54 patients

refractory and required salvage therapy with cyclosporine, infliximab, or colectomy as compared to *NOD2* wild-type patients (90.0 % vs. 38.1 %,  $p=0.004$ ). Nevertheless, there was no difference between carriers and non-carriers of *NOD2* polymorphisms regarding response to medical salvage therapy and therefore in the need for salvage colectomy (Table 3).

#### Long-term disease course—treatment requirements

The rate of steroid-dependence was similar between groups (33.3 % vs. 27.5 %,  $p=0.531$ ). Even though there was no statistical difference between carriers and non-carriers regarding the rate of steroid-resistance when the three polymorphisms were studied together, we did find that patients with the polymorphism R702 W (6 patients, 28.6 %) were more often resistant to steroids than non-carriers (18 patients, 10.3 %) ( $p=0.027$ ). There were no significant differences between genotypes regarding the proportion of patients treated with thiopurines or infliximab.

The colectomy rate was significantly higher in carriers of *NOD2* mutations than in non-carriers: 17.9 % (5 patients) as compared with 4.1 % (7 patients) ( $p=0.015$ ) (Table 4 and Fig. 2). The same behavior was observed when R702W polymorphism was considered individually (Table 4 and Fig. 2).

No patient deaths were recorded during follow-up.

#### Multivariate analysis

The above-described results that reached statistical significance were then tested in multivariate analysis considering age at diagnosis and extent of disease as covariates. All these correlations remained statistically significant, indicating that the *NOD2*-phenotype associations detected are independent from the age at diagnosis and the extent of disease (data not shown).

#### Discussion

IBD, including UC, has a great amount of heterogeneity, starting in the type and age of presentation, through natural history of disease and ending in the therapeutic requirements and response [17, 21, 22]. An old and still unachieved goal is to discover a way of predicting the disease evolution and thereby define a more appropriate and individually tailored monitoring and therapeutic approach [16–19]. The personalized choice of the treatment regimen may help to maximize efficacy, minimize delays to effective treatment, and improve safety and tolerability.

Therefore, an ultimate objective in the genomic study of IBD is to identify biologically relevant genotype–phenotype associations and to apply them to clinical practice [16, 17, 20]. In the past two decades, genetic variants identified as being

**Table 3** Severe colitis—incidence and therapy

Variables	All <i>NOD2</i> mutations			R702W polymorphism		
	Carriers <i>n</i> (%)	Non-carriers <i>n</i> (%)	<i>p</i>	Carriers <i>n</i> (%)	Non-carriers <i>n</i> (%)	<i>p</i>
Severe colitis <sup>a</sup>	10 (35.7 %)	42 (24.4 %)	0.206	8 (38.1 %)	44 (24.6 %)	0.182
IV steroid refractory <sup>b</sup>	9 (90.0 %)	16 (38.1 %)	0.004	7 (87.5 %)	18 (40.9 %)	0.022
CYA/IFX refractory <sup>c</sup>	2 (28.6 %)	2 (13.3 %)	0.565	2 (33.3 %)	2 (12.5 %)	0.292

IV intravenous, CYA cyclosporine, IFX infliximab

<sup>a</sup> Flare with severe activity according Truelove and Witts criteria and requiring admission and treatment with intravenous steroids [54, 59]<sup>b</sup> No response to intravenous steroids and required salvage therapy with cyclosporine, infliximab, or colectomy<sup>c</sup> No response to cyclosporine and/or infliximab and required salvage colectomy



**Table 4** Long term disease course—treatment requirements

Variables	All <i>NOD2</i> mutations			R702W polymorphism		
	Carrier <i>n</i> (%)	Non-carrier <i>n</i> (%)	<i>p</i>	Carrier <i>n</i> (%)	Non-carrier <i>n</i> (%)	<i>p</i>
Steroid-dependent <sup>a</sup>	9 (33.3 %)	47 (27.5 %)	0.531	7 (33.3 %)	49 (27.7 %)	0.587
Steroid refractory <sup>b</sup>	7 (25.0 %)	17 (10.1 %)	0.054	6 (28.6 %)	18 (10.3 %)	0.027
AZA/6-MP <sup>c</sup>	11 (39.3 %)	66 (38.4 %)	0.927	8 (38.1 %)	69 (38.5 %)	0.968
Infliximab <sup>d</sup>	6 (21.4 %)	20 (11.6 %)	0.220	5 (23.8 %)	21 (11.7 %)	0.161
Colectomy <sup>e</sup>	5 (17.9 %)	7 (4.1 %)	0.015	4 (19.0 %)	8 (4.5 %)	0.026

AZA azathioprine; 6-MP 6-Mercaptopurine

<sup>a</sup> Data available in 198 patients

<sup>b</sup> Data available in 196 patients

<sup>c</sup> Data available in 200 patients

<sup>d</sup> Data available in 200 patients

<sup>e</sup> Data available in 200 patients

associated with increased susceptibility to IBD were then subject to research in order to investigate whether they are also correlated with the disease phenotype. *NOD2*, the first gene linked with increased susceptibility to CD, has later been shown to be associated with ileal disease, early age of onset, stricturing, and/or penetrating phenotype and increased need

for surgery [5, 9, 10, 38–49]. Among the UC susceptibility genes, HLA DRB1\*0103 and the multidrug resistance gene 1 (MDR1/ABCB1) were also identified as being associated with extensive and severe disease [17, 23–37].


In UC, all genotype–phenotype association studies focus on genes which have previously demonstrated association with increased susceptibility to the disease [5, 17]. Thus, as *NOD2* has not been generally linked with UC susceptibility, there are no published studies of potential associations between *NOD2* genotype and UC phenotype [5]. However, this reasoning may produce a bias because a gene can be associated with a particular phenotype despite not being related with increase susceptibility to the disease. For example, Seghal et al. demonstrated that *NOD2* variants are associated with severe pouchitis, although these mutations do not increase the overall risk of pouchitis [20].

Taking this data into account, this paper aimed to clarify if *NOD2* mutations increased susceptibility to UC in Portugal and whether there are genotype–phenotype correlations in these patients. To our knowledge, this is the first study that sought potential associations between *NOD2* mutations and phenotype, natural history or therapeutic responsiveness in patients with UC.

In line with the evidence from the majority of previous studies, we found that *NOD2* mutations are not linked with increased susceptibility to UC in the Portuguese population [5, 10, 50].

In the study population, we found that there were no associations between *NOD2* mutations and demographic characteristics (age at onset, gender, and family history of IBD) or smoking habits. Similarly, the disease extent showed no correlation with *NOD2* mutation status.

Regarding the disease course during the first year following diagnosis, we found that patients with a mutation of the studied gene were more likely to receive steroids for a disease



**Fig. 2** Cumulative colectomy-free survival in patients with and without *NOD2* mutation and R702W polymorphism

flare (54.2 vs. 29.6 %,  $p=0.018$ ). Among patients who required steroids in this setting, the need for intravenous administration was significantly more frequent in those with the R702W polymorphism (90.0 % vs. 45.5 %,  $p=0.014$ ).

According to our results, there was no association of any genotype with the incidence of severe colitis, defined as a flare with severe activity according Truelove and Witts criteria and requiring admission and treatment with intravenous steroids [54, 59]. Nevertheless, *NOD2* mutations were significantly associated with intravenous-steroid refractoriness and, hence, with the need for salvage therapy with cyclosporine, infliximab, or colectomy ( $p=0.004$ ). By contrast, *NOD2* carrier status was not associated with the response to medical salvage therapy and therefore with the need for salvage colectomy, but the small number of patients with these events advises a careful interpretation.

In addition to severe colitis episodes, the course of UC can be indirectly evaluated through the therapeutic needs and responses, including steroid-dependence, steroid-resistance, need of immunosuppressive/immunomodulatory agents and colectomy rates. In our study cohort, even though the combined three key *NOD2* mutations were not associated with steroid-dependence or steroid-resistance, we found that carriers of the R702W polymorphism were more often resistant to steroids ( $p=0.027$ ). The need for immunosuppressants/immunomodulators showed no significant associations with *NOD2* mutations, even when R702W polymorphism was considered separately. However, both, R702W polymorphism alone and 3020insC/R702W/G908R variants together, were associated with increased need of colectomy (respectively,  $p=0.026$  and  $p=0.015$ ).

The age at diagnosis and the extent of disease are frequently and consistently identified as prognostic factors in UC [57]. In this context, the significant associations found between *NOD2* gene and UC phenotype characteristics, were included in a multivariate analysis using age at diagnosis and extent of disease as covariates. This evaluation has shown that the *NOD2* prognostic value detected in our work is independent of these two important variables.

Our data suggests that although *NOD2* genotype does not correlate with susceptibility to UC, the mutations of this gene appear to be associated with a more aggressive course of the disease. Similar findings were reported in CD, where *NOD2* carrier status has been associated not only with a more aggressive disease phenotype but also to an increased likelihood of steroid refractoriness and a higher need for surgery [5, 9, 10, 38–49].

Surprisingly, apart from our work, there is no other study regarding potential *NOD2* genotype–phenotype correlations in UC patients. Thus, further data from different and larger populations is needed to determine whether *NOD2* mutations lead to a predisposition to a more aggressive UC disease course and, if so, to identify the additional determinants

necessary for this increased susceptibility, namely their possible interactions with other genes, environmental factors, clinical features, and demographic data. A thorough investigation of these issues may improve knowledge of the disease pathophysiology, can shed light on the determinants of clinical UC heterogeneity and could lead to the development of new therapeutic paradigms.

This study has some limitations. Firstly, the size of the study population is relatively small. Secondly, the potential effect of other genetic and/or environmental factors and/or their interaction with *NOD2* mutations has not been evaluated. Thirdly, disease course, treatment requirements and response/remission rates were evaluated retrospectively. Finally, this work was performed in a teaching and referral hospital and therefore our results may not be applicable to institutions with different patient populations.

In conclusion, our study suggests that even though *NOD2* mutations do not confer an increased risk of UC in the Portuguese population, these genetic variants are associated with a more aggressive course of the disease, including greater need of steroids in the first year, increased incidence of intravenous-steroid refractoriness and a higher rate of colectomy. This is the first study that demonstrated a link between *NOD2* genotype and UC phenotype. Regional heterogeneity within the *NOD2* genotype in UC patients shows the importance of the genetic assessment and evaluation of its correlation with the phenotype in different populations [4, 5, 10, 12–15, 50]. In addition, other potential genetic predictors and detailed information about environmental exposure should be assessed in future studies, because the low-penetrance genetic effects of common SNPs may largely depend on interaction with other determinant factors. Hence, additional research, using larger patient groups as well as other populations and with the assessment of additional genetic and environmental factors, is required in order to unequivocally determine the role of *NOD2* variants in UC heterogeneity. This investigation will be essential to validate our data, to provide the rationale for identifying objective predictors of disease course and that could, ultimately, be an important step toward a personalized therapy in UC patients.

**Acknowledgments** This study was supported by research grants awarded by: Fundação para a Ciência e Tecnologia (SFRH/SINTD/60055/2009), Fundação Glaxo Smith Kline das Ciências da Saúde, Sociedade Portuguesa de Endoscopia Digestiva, Faculdade de Medicina da Universidade de Coimbra (Programa de Estímulo à Investigação, En 2011) and Centro de Estudos Ibéricos. These institutions had no role in any phase of this study.

We acknowledge all our colleagues who referred cases, and the patients for generously participating in the research. We thank Dr. Jorge Tomaz and Dr. Ana Esesúmagá for providing biological material (whole blood) from blood donors. We are indebted to Carlos Alberto for this expert technical assistance.

**Conflicts of interest/disclosure** The authors have no potential conflicts of interest.

## References

- Podolsky DK (2002) Inflammatory bowel disease. *N Engl J Med* 347:417–429
- Brant SR (2013) Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. *Clin Gastroenterol Hepatol* 11:22–26
- Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY et al (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 491:119–124
- Waterman M, Xu W, Stempak JM, Milgrom R, Bernstein CN, Griffiths AM et al (2011) Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. *Inflamm Bowel Dis* 17:1936–1942
- Cho JH, Brant SR (2011) Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology* 140:1704–1712
- Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411:599–603
- Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411:603–606
- Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T et al (2003) Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. *Gastroenterology* 124:140–146
- Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S et al (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. *Lancet* 357:1925–1928
- Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S et al (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. *Am J Hum Genet* 70:845–857
- Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U et al (2003) CARD15/NOD2 gene variants are associated with familiarly occurring and complicated forms of Crohn's disease. *Gut* 52:558–562
- Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A et al (2005) Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. *World J Gastroenterol* 11:681–685
- Pugazhendhi S, Santhanam S, Venkataraman J, Creveaux I, Ramakrishna BS (2013) NOD2 gene mutations associate weakly with ulcerative colitis but not with Crohn's disease in Indian patients with inflammatory bowel disease. *Gene* 512:309–313
- Yun J, Xu CT, Pan BR (2009) Epidemiology and gene markers of ulcerative colitis in the Chinese. *World J Gastroenterol* 15:788–803
- Juyal G, Amre D, Midha V, Sood A, Seidman E, Thelma BK (2007) Evidence of allelic heterogeneity for associations between the NOD2/CARD15 gene and ulcerative colitis among North Indians. *Aliment Pharmacol Ther* 26:1325–1332
- Niess JH, Klaus J, Stephani J, Pflüger C, Degenkolb N, Spaniol U et al (2012) NOD2 polymorphism predicts response to treatment in Crohn's disease—first steps to a personalized therapy. *Dig Dis Sci* 57:879–886
- Haritunians T, Taylor KD, Targan SR, Dubinsky M, Ippoliti A, Kwon S et al (2010) Genetic predictors of medically refractory ulcerative colitis. *Inflamm Bowel Dis* 16:1830–1840
- Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J (2006) Predictors of Crohn's disease. *Gastroenterology* 130:650–656
- Loly C, Belaiche J, Louis E (2008) Predictors of severe Crohn's disease. *Scand J Gastroenterol* 43:948–954
- Sehgal R, Berg A, Hegarty JP, Kelly AA, Lin Z, Poritz LS et al (2010) NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. *Dis Colon Rectum* 53:1487–1494
- Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K et al (2013) Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. *Inflamm Bowel Dis* 19:1218–1223
- Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekblom A et al (2013) Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005–2009—results from the IBD Cohort of the Uppsala Region (ICURE). *J Crohns Colitis* 7(9):e351–e357
- Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S et al (1997) Genetic markers may predict disease behavior in patients with ulcerative colitis. *Gastroenterology* 112:1845–1853
- Bouma G, Crusius JB, García-González MA, Meijer BU, Hellemans HP, Hakvoort RJ et al (1999) Genetic markers in clinically well defined patients with ulcerative colitis (UC). *Clin Exp Immunol* 115:294–300
- de la Concha EG, Fernandez-Arquero M, Lopez-Nava G, Martin E, Allcock RJ, Conejero L et al (2000) Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. *Gastroenterology* 119:1491–1495
- Yamamoto-Furusho JK, Uscanga LF, Vargas-Alarcón G, Ruiz-Morales JA, Higuera L, Cutiño T et al (2003) Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. *Hum Immunol* 64:119–123
- Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI et al (2003) The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. *Tissue Antigens* 62:527–535
- Fernández L, Núñez C, Mendoza JL, Urcelay E, Fernández-Arquero M, Taxonera C et al (2005) A recombined haplotype in the major histocompatibility region contains a cluster of genes conferring high susceptibility to ulcerative colitis in the Spanish population. *Inflamm Bowel Dis* 11:785–791
- Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R et al (2003) MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. *Am J Hum Genet* 73:1282–1292
- Ho GT, Gaya DR, Satsangi J (2005) Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player? *Inflamm Bowel Dis* 11:1013–1019
- Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J (2006) ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a genome-wide haplotype tagging approach. *Hum Mol Genet* 15:797–805
- Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ et al (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. *Nat Genet* 40:710–712
- Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G et al (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. *Nat Genet* 40:1319–1323
- Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V et al (2009) Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. *Nat Genet* 41:216–220
- Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA et al (2009) Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. *Gastroenterology* 136:523–529



36. Yang H, Rotter JJ, Toyoda H, Landers C, Tyran D, McElree CK et al (1993) Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. *J Clin Invest* 92:1080–1084
37. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ (1999) HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. *Gut* 45:395–401
38. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ et al (2002) Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. *Gastroenterology* 123:679–688
39. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR et al (2002) The molecular classification of the clinical manifestations of Crohn's disease. *Gastroenterology* 122:854–866
40. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ et al (2002) The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. *Gastroenterology* 122:867–874
41. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S et al (2002) Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. *Lancet* 359:1661–1665
42. Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A et al (2002) CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. *Am J Hum Genet* 71:74–83
43. Oostenbrug LE, Nolte IM, Oosterom E, van der Steege G, te Meerman GJ, van Dullemen HM et al (2006) CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: an association study and pooled analysis. *Dig Liver Dis* 38:834–845
44. Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G et al (2004) Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977–2001. *World J Gastroenterol* 10:404–409
45. Newman B, Siminovich KA (2005) Recent advances in the genetics of inflammatory bowel disease. *Curr Opin Gastroenterol* 21:401–407
46. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK (2003) CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. *Gastroenterology* 124:993–1000
47. Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K et al (2006) Homozygosity for the CARD15 frameshift mutation 1007 fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. *Scand J Gastroenterol* 41:1421–1432
48. Seiderer J, Brand S, Herrmann KA, Schnitzler F, Hatz R, Crispin A et al (2006) Predictive value of the CARD15 variant 1007 fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. *Inflamm Bowel Dis* 12:1114–1121
49. Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S et al (2009) Genetic risk profiling and prediction of disease course in Crohn's disease patients. *Clin Gastroenterol Hepatol* 7:972–980
50. Rigoli L, Romano C, Caruso RA, Lo Presti MA, Di Bella C, Procopio V et al (2008) Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease. *World J Gastroenterol* 14:4454–4461
51. Lennard-Jones JE (1989) Classification of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 170:2–6, discussion 16–9
52. Sands BE (2004) From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. *Gastroenterology* 126:1518–1532
53. Podolsky DK (1991) Inflammatory bowel disease (2). *N Engl J Med* 325:1008–1016
54. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. *J Crohns Colitis* 6:965–990
55. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 6:991–1030
56. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G et al (2013) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. *J Crohns Colitis* 7:1–33
57. Zallot C, Peyrin-Biroulet L (2012) Clinical risk factors for complicated disease: how reliable are they? *Dig Dis* 30:67–72
58. Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 2:1041–1048
59. Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 55:749–753